Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study

References

• COVID-19 Map. [cited November 2, 2020]. Available from: https://coronavirus.jhu.edu/map.html
   Google Scholar
• Singhal TA. Review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–286.
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. LANCET. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020 Mar 16. DOI:10.1093/cid/ciaa270.
   PubMed Web of Science ®Google Scholar
• Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–420.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Clinical management of severe acute respiratory infection when novel coronavirus (‎‎‎‎‎2019-nCoV)‎‎‎‎‎ infection is suspected: interim guidance, 28 January 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330–1341.
   PubMed Web of Science ®Google Scholar
• Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–684.
   PubMed Web of Science ®Google Scholar
• Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chin J Tubercul Respirat Dis. 2020;43(3):183–184.
   Google Scholar
• Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854–887.
   PubMed Web of Science ®Google Scholar
• Kow CS, Hasan SS. Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in coronavirus disease 2019? Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa1423
   Google Scholar
• Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441–1452.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767.
   PubMed Web of Science ®Google Scholar
• Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):e98–e106.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun W, Svendsen ER, et al. Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. Crit Care. 2015;19:46.
   PubMed Web of Science ®Google Scholar
• Song YG, Shin HS. COVID-19, a clinical syndrome manifesting as hypersensitivity pneumonitis. Infect Chemother. 2020;52(1):110–112.
   PubMed Web of Science ®Google Scholar
• Zheng C, Wang J, Guo H, et al. Risk-adapted treatment strategy For COVID-19 patients. Inter J Infect Dis. 2020;94:74–77.
   PubMed Web of Science ®Google Scholar
• Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14(11):1149–1163.
   PubMed Web of Science ®Google Scholar
• Clinical Data Collection. The COVID-19 case report forms (CRFs). [cited November 2, 2020]. Available from: https://isaric.tghn.org/COVID-19-CRF/
   Google Scholar
• Cao B, Gao H, Zhou B, et al. Adjuvant corticosteroid treatment in adults with influenza a (H7N9) viral pneumonia. Crit Care Med. 2016;44(6):E318–E328.
   PubMed Web of Science ®Google Scholar
• Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–1329.
   PubMed Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327–331.
   PubMed Web of Science ®Google Scholar
• Dai J, Xiong Y, Li H, et al. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review. Clin Rheumatol. 2020;39(7):2031–2037.
   PubMed Web of Science ®Google Scholar
• Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
   PubMed Web of Science ®Google Scholar
• Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020;81(1):147–178.
   Web of Science ®Google Scholar
• Kolilekas L, Loverdos K, Giannakaki S, et al. Can steroids reverse the severe COVID-19 induced ‘cytokine storm’? J Med Virol. 2020;92(11):2866–2869.
   PubMed Web of Science ®Google Scholar
• Maes T, Bracke K, Brusselle GGCOVID-19. COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2020;202(1):8–10.
   PubMed Web of Science ®Google Scholar
• So C, Ro S, Murakami M, et al. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respirol Case Rep. 2020;8(6):e00596–e00596.
   PubMed Web of Science ®Google Scholar
• Taboada M, Caruezo V, Naveira A, et al. Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease. J Clin Anesth. 2020;66:109926.
   PubMed Web of Science ®Google Scholar
• Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne). 2020;7:170.
   PubMed Web of Science ®Google Scholar
• Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ = Journal De l’Association Medicale Canadienne. 2020;192(27):E756–E767.
   PubMed Web of Science ®Google Scholar
• Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118.
   PubMed Web of Science ®Google Scholar
• Russell B, Moss C, Rigg A, et al. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? ECANCERMEDICALSCIENCE. 2020;14:1023.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81(1):e13–e20.
   PubMed Web of Science ®Google Scholar
• Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock. 2020;54(5):638–643.
   PubMed Web of Science ®Google Scholar
• Matthay MA, Wick KD. Corticosteroids, COVID-19 pneumonia and acute respiratory distress syndrome. J Clin Invest. 2020. DOI:10.1172/JCI143331
   PubMed Web of Science ®Google Scholar
• Saghazadeh A, Rezaei N. Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol. 2020 Jul;84:106560.
   PubMed Web of Science ®Google Scholar
• Singh AK, Majumdar S, Singh R, et al. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab Syndr. 2020 Sep;14(5):971–978.
   PubMed Web of Science ®Google Scholar